Chinese startup Gestala, led by Phoenix Peng, has raised $21.6 million in a heavily oversubscribed early-stage funding round, marking the largest such investment in China's BCI industry. The company is developing a non-invasive, ultrasound-based brain-computer interface and plans to use the funds for R&D, team expansion, and building a manufacturing facility.
The main topics covered are the competitive BCI landscape, Gestala's funding and valuation, and the technical and commercial potential of ultrasound BCI technology.
Gestala aims to address the risks of surgical implants by using ultrasound to monitor and stimulate broader brain areas. The startup is initially targeting chronic pain management and exploring applications for various mental health and neurological conditions.
Despite geopolitical tensions, CEO Peng advocates for U.S.-China collaboration in deep-tech, citing complementary strengths in clinical research and scientific talent. The company believes its speed and ability to leverage China's manufacturing scale provide a competitive advantage.
Elon Musk’s Neuralink and OpenAI-backed Merge Labs are pushing forward with brain–computer interface (BCI) technology in the U.S. Meanwhile, Chinese serial entrepreneur Phoenix Peng is building rival efforts through two startups: NeuroXess, which develops implantable BCI systems, and a second company, Gestala, developing non-invasive ultrasound-based BCIs.
Gestala has raised $21.6 million (CN¥150 million) just two months after launching, at a valuation of $100 million to $200 million, founder and CEO Phoenix Peng told TechCrunch.
The round, co-led by Guosheng Capital and Dalton Venture with participation from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin and Seas Capital, was heavily oversubscribed, with investor commitments totaling more than $58 million, Peng added.
This is the largest early-stage funding in China’s BCI industry. Peng will use the money towards R&D, expanding the team from 15 to about 35 employees by year-end, and building a manufacturing facility in China. The three-month-old startup aims to complete its first-generation prototype by the end of the year.
The global BCI industry is currently experiencing an investment surge in ultrasound technology. Gestala is the first ultrasound BCI company in China, though not the first globally. Several ultrasound BCI startups have emerged in the U.S. in recent years, including Merge Labs, which is among the largest.
Peng believes ultrasound could represent the next generation of brain–computer interface technology, offering the potential for broader, whole-brain access and new ways to interact with neural activity.
The founder says non-invasive ultrasound could address one of the biggest barriers to BCI adoption: the risks associated with brain surgery. Compared with implanted electrode systems, the technology can monitor a larger portion of the brain, including deep neural circuits. Using phased-array ultrasound, the system can also precisely stimulate or suppress neural activity without the need for surgery, he explained.
Disrupt 2026: The tech ecosystem, all in one room
Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to $400.
Save up to $300 or 30% to TechCrunch Founder Summit
1,000+ founders and investors come together at TechCrunch Founder Summit 2026 for a full day focused on growth, execution, and real-world scaling. Learn from founders and investors who have shaped the industry. Connect with peers navigating similar growth stages. Walk away with tactics you can apply immediately
Offer ends March 13.
Despite rising geopolitical tensions, Peng still hopes the U.S. and China can collaborate on deep-technology research.
“Both countries bring different strengths,” Peng said. “China offers large-scale clinical research capacity and efficient supply chains, while the U.S. has world-class scientific talent.” Joint efforts could also focus on building large clinical datasets to support global neuroscience research, he mentioned.
The company is exploring several uses for its tech. Medically, chronic pain management is the startup’s lead program. Chronic pain affects large populations in both the U.S. and China, and existing academic studies suggest ultrasound stimulation can significantly reduce pain levels, Peng said.
The startup is also studying applications in mental health conditions, including depression, PTSD, autism and OCD, as well as stroke rehabilitation. Other longer-term targets include Alzheimer’s disease, essential tremor and Parkinson’s disease. In total, the company is researching six to eight potential indications, though most remain at the early research stage rather than in clinical trials.
Gestala says its advantage over global rivals comes down to speed and scale. By leveraging China’s integrated manufacturing ecosystem, the startup believes it can move from development to production faster than many international competitors.
The company is also working with major Chinese hospitals to accelerate clinical trials at significantly lower costs — roughly 20% to 33% of comparable studies in the U.S. or Europe. At the same time, Gestala is building what it calls an “Ultrasound Brain Bank,” a large clinical dataset designed to train AI models to decode brain signals and support future neurological diagnostics.
Meridiano
